Loading...
A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was...
Na minha lista:
| Udgivet i: | Vaccines (Basel) |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7564945/ https://ncbi.nlm.nih.gov/pubmed/32887369 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8030498 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|